miRoncol

Executive Summary

miRoncol is a privately held biotech company founded in 2020 and headquartered in New York, focusing on microRNA-based therapeutics and diagnostics for oncology. The company leverages the regulatory potential of microRNAs to develop novel cancer treatments and companion diagnostics. Currently in preclinical stage, miRoncol's approach aims to address key challenges in oncology by modulating gene expression networks implicated in tumor progression and drug resistance. While the company has not yet disclosed specific pipeline candidates or trial timelines, its microRNA platform holds promise for both monotherapy and combination strategies. The early-stage nature implies significant technical and regulatory risks, but the growing interest in RNA therapeutics provides a favorable backdrop. Key upcoming catalysts include the filing of an Investigational New Drug (IND) application for its lead candidate, anticipated within the next 12-18 months; initial preclinical efficacy and toxicity data readouts; and potential partnership or funding announcements. Successful execution could lead to first-in-human trials, while failure to advance may necessitate platform pivot.

Upcoming Catalysts (preview)

• Q3 2027IND Filing for Lead Candidate30% success
• Q4 2026Preclinical Data Presentation at Major Conference70% success
• Q1 2027Series A Funding Round50% success